Drug Trial Radar · NCT05091567
A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer
Last checked: Nov 20, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
660
Actual
Start
Nov 18, 2021
Primary completion
Jul 29, 2024
Study completion Feb 28, 2028
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- Collaborators
- Jazz Pharmaceuticals
- First posted
- Oct 25, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Study GO43104 is a Phase III, randomized, open-label, multicenter study of lurbinectedin in combination with atezolizumab compared with atezolizumab alone administered as maintenance therapy in participants with extensive-stage small-cell lung cancer (ES-SCLC) after first-line induction therapy with carboplatin, etoposide, and atezolizumab. The study consists of 2 phases: an induction phase and a maintenance phase. Participants need to have an ongoing response or stable disease per the Response Evaluation Criteria in Solid Tumor (RECIST) v1.1 criteria after completion of 4 cycles of carboplatin, etoposide, and atezolizumab induction treatment in order to be considered for eligibility screening for the maintenance phase. Eligible participants will be randomized in a 1:1 ratio to receive either lurbinectedin plus atezolizumab or atezolizumab in the maintenance phase.
Conditions
- Small-Cell Lung Cancer
Interventions
AtezolizumabDrug
Atezolizumab will be administered intravenously at a fixed dose of 1200 mg on Day 1 of each 21-day cycle for 4 cycles in the induction phase. Atezolizumab will be administered intravenously at a fixed dose of 1200 mg on Day 1 of each 21-day cycle in the maintenance phase.
LurbinectedinDrug
Lurbinectedin 3.2 mg/m² will be administered intravenously on Day 1 of each 21-day cycle in the maintenance phase.
CarboplatinDrug
Carboplatin will be administered according to the standard of care treatment for 4 cycles in the induction phase.
EtoposideDrug
Etoposide will be administered according to the standard of care treatment for 4 cycles in the induction phase.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Randomized Phase: Independent Review Facility (IRF) - Assessed Progression Free Survival (PFS)Time frame: Up to 26 months
- Randomized Phase: Overall Survival (OS)Time frame: Up to 26 months
Locations
93 sites in 13 countries. Site status is shown where the registry gives one.
Northwest Georgia Oncology Centers, a Service of WellStar Cobb Hospital
Marietta, Georgia
Illinois Cancer Care
Peoria, Illinois
New England Cancer Specialists
Scarborough, Maine
Dana Farber Cancer Institute
Boston, Massachusetts
Cancer & Hematology Centers of Western Michigan
Grand Rapids, Michigan
Clinical Research Alliance
Westbury, New York
The Mark H. Zangmeister Ctr
Columbus, Ohio
Rhode Island Hospital
Providence, Rhode Island
Hollings Cancer Center
Charleston, South Carolina
Greco-Hainesworth Centers for Research
Chattanooga, Tennessee
West Clinic
Germantown, Tennessee
Sarah Cannon Research Institute / Tennessee Oncology
Nashville, Tennessee
Institut Jules Bordet
Anderlecht, Belgium
Jessa Zkh (Campus Virga Jesse)
Hasselt, Belgium
UZ Leuven Gasthuisberg
Leuven, Belgium
AZ St Maarten Campus Leopoldstr
Mechelen, Belgium
CHU UCL Mont-Godinne
Mont-godinne, Belgium
Vitaz
Sint-Niklaas, Belgium
Zentralklinik Bad Berka GmbH
Bad Berka, Germany
Evang. Lungenklinik Berlin Klinik für Pneumologie
Berlin, Germany
Helios Klinikum Emil von Behring GmbH
Berlin, Germany
Klinikum Chemnitz gGmbH
Chemnitz, Germany
KEM/Evang. Kliniken Essen Mitte gGmbH
Essen, Germany
Niels-Stensen-Kliniken Franziskus-Hospital Harderberg GmbH
Georgsmarienhütte, Germany
LungenClinic Großhansdorf GmbH
Großhansdorf, Germany
Krankenhaus Martha-Maria Halle-Doelau gGmbH
Halle, Germany
Fachklinik für Lungenerkrankungen
Immenhausen, Germany
Universitätsklinikum Schleswig-Holstein
Lübeck, Germany
Asklepios Klinik Gauting
München-Gauting, Germany
Sotiria Thoracic Diseases Hospital of Athens
Athens, Greece
Errikos Dynan Hospital
Athens, Greece
University Hospital of Larissa
Larissa, Greece
Euromedical General Clinic of Thessaloniki
Thessaloniki, Greece
Ag. Loukas Hospital
Thessaloniki, Greece
Diavalkaniko Hospital
Thessaloniki, Greece
Orszagos Koranyi Pulmonologiai Intezet
Budapest, Hungary
Pécsi Tudományegyetem
Pécs, Hungary
Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz-Rend.Int.
Szolnok, Hungary
Tudogyogyintezet Torokbalint
Törökbálint, Hungary
AUSL della Romagna
Ravenna, Emilia-Romagna, Italy
Showing 40 of 93 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.